While serving as Senior vice president and chief compliance officer of Amgen Inc., Anna Richo was responsible for the global pharmaceutical company’s compliance and business ethics programs. Anna Richo reported on environmental sustainability efforts for Amgen. An international biotechnology leader, Amgen continues to remain focused on using resources wisely and operating in an environmentally responsible manner. Amgen is committed to improved efficiency in research, in development of medicines, and in processes of manufacturing. Known for its innovative building policies, Amgen plans, constructs, and operates its facilities with a conservation mindset. Amgen sites around the world are evidence of this environmentally responsible construction. In Singapore, a state-of-the-art biomanufacturing plant has been built that will drastically reduce water use, solid waste output, and carbon emissions. Amgen’s considerable water conservation efforts in California and Puerto Rico have been stepped up even more in response to drought. Over the past several years, Amgen has increased energy conservation practices, which has largely reduced carbon emissions in the company. Amgen also lists renewable and alternative energy as a part of its long-term plans. This biology-focused company has a deep appreciation for natural resources and is continually looking for new ways to limit its impact on the environment.
0 Comments
A graduate of the DePaul University, College of Law, Anna Richo has almost 25 years of experience in the bioscience and health care industries. Recognized by FiercePharma as one of the top 15 women in the industry in 2009, Anna Richo is currently the Executive Vice President and General Counsel of UCB. Prior to UCB, Anna Richo was Senior Vice President and Chief Compliance Officer at Amgen Inc.
Dedicated to improving patients’ health or saving lives through innovative biotechnology, Amgen Inc., has been in business since 1980. Established on the principles of teamwork, quality, ethics, and communication, Amgen is committed to its science-based approach and strives to create value for stockholders, patients, and staff. With locations around the globe, Amgen has consistently ranked among the world’s top science employers. One of the first to develop therapeutic proteins able to precisely target disease, Amgen maintains a commitment to focusing on the biology of disease, allowing scientists to examine its molecular structure prior to considering which method or medicine will be the most effective. To that end, its research and development are guided by scientific innovations and investments to address serious illnesses. In addition to conducting wide range of ongoing clinical trials and developing effective medicines, Amgen offers patients its Amgen Assist program, which helps them pay for medications through reimbursement and other support options. |
AuthorAs of November 1, 2012, Anna Richo became Executive Vice President and General Counsel of UCB, a biopharmaceutical company headquartered in Brussels, Belgium. Archives
August 2018
Categories
All
|